Résumé
Advanced glycation end products [AGEs] and their receptor [RAGE] system play an important role in the development of diabetic vascular complications. Recently, an endogenous secretory RAGE [esRAGE] has been identified as a novel variant, which lacks the transmembrane domain and is secreted in human sera. Interestingly, it was reported that esRAGE binds AGEs ligands and is capable of neutralizing the actions of AGEs on endothelial cells I cultures. 88 subjects were involved in this study, they were divided into three groups: type 2 diabetes patients group [n=33], obesity group [n=33], control group [n=22]. We determined plasma esRAGE levels of this subjects using ELISA, and then we investigated the relationship between esRAGE and HbA1c in both diabetic patients and obesity subjects. Plasma esRAGE levels were significantly lower in type 2 diabetes patients [0.26 +/- 0.06 ng/ml] and obesity subjects [0.27 +/- 0.07 ng/ml] compared to control group [0.37 +/- 0.13 ng/ml]. The study also showed significantly an inversely correlated between esRAGE and HbA1c in both diabetic patients and obesity subjects. Plasma esRAGE levels were lower in type 2 diabetes patients and obesity group compared to control group, and were inversely correlated with glucose control in those groups